Table 1.

Characteristics of the patients

Characteristics	Patients with haematologic malignancy (n = 25)	Patients without haematologic malignancy (n = 25)	p
Age (years)a	64.8 ± 16.0	66.7 ± 11.1	NS
Male genderb	19 (76)	19 (76)	NS
Haematologic cancerb
- AML   - ALL   - DLBCL   - Hodgkin lymphoma   - Low-grade lymphoma   - CLL   - MM	8 (32) 3 (12) 5 (20) 1 (4) 3 (12) 1 (4) 4 (16)
Number of oncologic treatment linesb
- 0   - 1   - 2   - 3	2 (8) 17 (68) 5 (20) 1 (4)
Comorbiditiesb
- Undernutrition   - Hypertension   - Cardiovascular disease   - Dyslipidaemia   - Diabetes   - Currently smoking   - Chronic lung disease   - Chronic kidney failure	16 (64) 10 (40) 8 (32) 7 (28) 5 (20) 5 (20) 4 (16) 1 (4)	0 (0) 11 (44) 4 (16) 8 (32) 14 (56) 2 (8) 4 (16) 3 (12)	< 0.001 NS NS NS 0.019 NS NS NS
Symptomsb   - Oxygen need   - Fever   - ARDS	21 (84) 16 (64) 15 (60) 5 (20)	25 (100) 25 (100) 18 (72) 1 (4)
Minimal Cta	17.2 ± 5.2	26.5 ± 5.1	< 0.0001
Days of RT-PCR positivitya	21.2 ± 15.9	7.4 ± 5.6	< 0.01
Grade of lung involvementb
- No lesion   - Minimal   - Moderate   - Intermediate   - Severe   - Critical	2 (10.5) 6 (31.6) 2 (10.5) 5 (26.3) 3 (15.8) 1 (5.3)	0 (0) 1 (4) 12 (48) 10 (40) 2 (8) 0 (0)	NS 0.032 0.01 NS NS NS
COVID-19 managementb
- Heparins   - Antibiotics   - AZT   - Dexamethasone   - Anakinra   - Ruxolitinib   - HCQ   - Remdesivir	19 (76) 20 (80) 10 (40) 9 (36) 7 (28) 4 (16) 3 (12) 2 (8)	25 (100) 25 (100) 24 (96) 25 (100) 1 (4) 3 (12) 8 (32) 0 (0)	0.022 NS  < 0.0001  < 0.0001 0.049 NS NS NS
Oxygen durationa	11.2 ± 13.6	9.9 ± 4.9	NS
Mechanical ventilationb	5 (20)	1 (4)	NS
ICU transferb	9 (36)	6 (24)	NS
Deathb	10 (40)	1 (4)	< 0.001

^amean ± standard deviation

^bn (%)

NS, non-significant; AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; DLBCL, diffuse large B cell lymphoma; CLL, chronic lymphoid leukaemia; MM, multiple myeloma; ARDS, acute respiratory distress syndrome; Ct, cycle threshold; AZT, azithromycin; HCQ, hydroxychloroquine; ICU, intensive care unit